1. Aghajanian GK, Sprouse JS, Rasmussen K. Physiology of the midbrain serotonin system. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:141–149.

2. Andrade R, Nicoll RA. Soc Neurosci Abstr 1985:11:597.

3. Andrade R, Nicoll RA. Pharmacologically distinct actions of serotonin on single pyramidal neurons of the rat hippocampus recorded in vitro. J Physiol Lond 1987;394:99–124.

4. Aston-Jones G, Ennis M, Pieribone VA, Nickell WT, Shipley MT. The brain nucleus locus coeruleus: restricted afferent control of a broad efferent network. Science 1986;234:734–737.

5. Azmitia EC, Whitaker-Azmitia PM. Awakening the sleeping giant: anatomy and plasticity of the brain serotonergic system. J Clin Psychiatry 1991;52(12,Suppl):4–16.

6. Barrett JE, Witkin JM, Mansbach RS, Skolnick P, Weissman BA. Behavioral studies with anxiolytic drugs. III. Antipunishment actions of buspirone in the pigeon do not involve benzodiazepine receptor mechanisms. J Pharmacol Exp Ther 1986;238:1009–1013.

7. Beck SG, Clarke WP, Goldfarb J. Spiperone differentiates multiple 5-hydroxytryptamine responses in rat hippocampal slices in vitro. Eur J Pharmacol 1985;116:195–197.

8. Blier P, De Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987;7(6,Suppl):24S–35S.

9. Bressa GM, Marini S, Gregori S. Serotonin S2 receptors blockade and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam. Int J Clin Pharmacol Res 1987;7(2):111–119.

10. Charney DS, Redmond DE. Neurobiological mechanisms in human anxiety: evidence supporting central noradrenergic hyperactivity. Neuropharmacology 1983;22:1531–1536.

11. Charney DS, Woods SW, Goodman WK, Heninger GR. Serotonin function in anxiety. II. Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology 1987;92(1):14–24.

12. Coccaro EF, Siever LJ, Klar HM, Maurer G, et al. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989;46(7):587–599.

13. Cohn JB, Bowden CL, Fisher JG, Rodos JJ. Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med 1986;80(3B):10–16.

14. Cohn JB, Wilcox CS. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double blind study. J Clin Psychiatry 1986;47(8):409–412.

15. Coplan JD, Goetz R, Klein DF, Gorman JM, Papp LA. Determinants of lactate-induced panic: an extended sample review. Presented at the American Psychiatric Association, 1992, New Orleans, Louisiana.

16. Coplan JD, Gorman JM, Klein DF. Serotonin related functions in panic-anxiety: a critical overview. Neuropsychopharmacology 1992a;6(3):189–200.

17. Coplan JD, Gorman JM. Detectable levels of fluoxetine metabolites after discontinuation; an unexpected serotonin syndrome. Am J Psychiatry 1993;150(5):837.

18. Cunningham KA, Callahan PM, Appel JB. Discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT): implications for understanding the actions of novel anxiolytics. Eur J Pharmacol 1987;138:29–36.

19. Daval G, Verge D, Basbaum AI, et al. Autoradiographic evidence of serotonin I binding sites on primary afferent fibres in the dorsal horn of the rat spinal cord. Neurosci Lett 1987;83:71–76.

20. Delgado PL, Price LH, Miller HL, et al. Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol Bull 1991;27:321–330.

21. Den Boer JA, Westenberg HGM. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 1990;102(1):85–94.

22. Fabre LF. Double-blind comparison of buspirone with diazepam in anxious patients. Curr Ther Res 1987;41(5):751–759.

23. Fabre LF. Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychiatry 1990;51(Suppl): 55–61.

24. Fuller RW, Perry KW. Effects of buspirone and its metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats. J Pharmacol Exp Ther 1989;248(1):50–6.

25. Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. Br J Pharmacol Chemother 1957;12:323–328.

26. Glaser T, Traber J. Buspirone: action on serotonin receptors in calf hippocampus. Eur J Pharmacol 1983;88:137–138.

27. Goddard AW, Goodman WK, Woods SW, Heninger GR, Charney DS, Price LH. Effects of tryptophan depletion on panic anxiety. American College of Neuropsychopharmacology, 1992, San Juan, Puerto Rico. (abst).

28. Goldberg HL, Finnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 1979;136(9):1184–1187.

29. Hamik A, Peroutka SJ. 1-(m-Chlorophenyl) piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 1989;25:569–575.

30. Harrington MA, Zhong P, Garlow SJ, Ciaranello RD. Molecular biology of serotonin receptors. J Clin Psychiatry 1992; 53(10,Suppl):8–27.

31. Heninger GR, Charney DS, Sternberg DE. Serotonergic function in depression. Prolactin response to intravenous tryptophan in depressed patients and healthy subjects. Arch Gen Psychiatry 1984;41:398–402.

32. Jenkins SW, Robinson DS, Fabre LF Jr, Andary JJ, Messina ME, Reich LA. Gepirone in the treatment of major depression. J Clin Psychopharmacol 1990;10(3,Suppl):77S–85S.

33. Kahn RJ, McNair DM, Frankenthaler LM. Tricyclic treatment of generalized anxiety disorder. Special issue: drug treatment of anxiety disorders. J Affective Disord 1987;13(2):145–151.

34. Kahn RS, Asnis GM, Wetzler S, Van Praag HM. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology 1988;96(3):360–364.

35. Kendall DA, Nahorski SR. 5-Hydroxytrptamine stimulated inositol phospholipid hydrolysis in rat cerebral cortex slices: pharmacological characterization and effects of antidepressants. J Pharmacol Exp Ther 1985;233:473–479.

36. Klein DF, Coplan JD, Gorman JM. Theoretical and empirical basis for serotonergic drug use in panic avoidance behavior. In: Cassano GB, Akiskal HS, eds. Serotonin-related psychiatric syndromes: clinical and therapeutic links. London: Royal Society of Medicine Services Limited; 1991:93–97.

37. Klein DF, Gittelman R, Quitkin F, Rifkin A. Diagnosis and drug treatment. 2nd ed. Baltimore: Williams & Wilkins; 1980.

38. Lesch KP. 5-HT1A receptor responsivity in anxiety disorders and depression. Prog Neuropsychopharmacol Biol Psychiatry 1991; 15(6):723–733.

39. Lesch KP, Hoh A, Disselkamp-Tietze J, Wiesmann M, Osterheider M, Schulte HM. 5-Hydroxytryptamine1A receptor responsivity in obsessive-compulsive disorder. Comparison of patients and controls. Arch Gen Psychiatry 1991;48(6):540–547.

40. Lesch KP, Hoh A, Schulte HM, Osterheider M, Muller T. Long term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive–compulsive disorder. Psychopharmacology 1991; 105(3):415–420.

41. Lesch KP, Wiesmann M, Hoh A, et al. 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology 1992;106(1):111–117.

42. Lucki I, Wieland S. 5-Hydroxytryptamine1A receptors and behavioral responses. Neuropsychopharmacology 1990;3:481–493.

43. Markovitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive–compulsive disorder. Am J Psychiatry 1990;147(6):798–800.

44. McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1993;150(4): 647–649.

45. Middlemiss DN, Fozard JR. 8-Hydroxy-2(di-n-propylamino)tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur J Pharmacol 1983;90:151–153.

46. Millan MJ, Rivet JM, Canton H, LeMarouille-Girardon S, Gobert A. Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists. J Pharmacol Exp Ther 1993;264(3):1364–1376.

47. Morgane PJ, Jacobs MS. Raphe projections to the locus coeruleus in the rat. Brain Res Bull 1979;4(4):519–534.

48. Munjack DJ, Brun SJ, Baltazar PL, et al. A pilot study of buspirone in the treatment of social phobia. J Anxiety Disord 1991;5:87–98.

49. Pedigo NW, Yamamura HI, Nelson DL. Discrimination of multiple [3H]-5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. J Neurochem 1981;36:220–226.

50. Peroutka SJ, Sleight AJ, McCarthy BG, Pierce PA, Schmidt AW, Hekmatpanah CR. The clinical utility of pharmacological agents that act at serotonin receptors. J Neuropsychiatry Clin Neurosci 1989;1:253–262.

51. Peroutka SJ, Snyder SH. Long term antidepressant treatment lowers spiroperidol-labeled serotonin receptor binding. Science 1980;210: 88–90.

52. Petracca A, Nisita C, McNair D, Melis G, Guerani G, Cassano GB. Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone. J Clin Psychiatry 1990;51(Suppl):31–39.

53. Pohl R, Balon R, Yeragani VK, Gershon S. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 1989;22(Suppl 1):60–67.

54. Price LH, Charney DS, Delgado PL, et al. Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan: serotonergic function and the mechanism of antidepressant action. Arch Gen Psychiatry 1989;46(7):625–631.

55. Rausch JL, Ruegg R, Moeller FG. Gepirone as a 5-HT1A agonist in the treatment of major depression. Psychopharmacol Bull 1990;26(2):169–171.

56. Riblet LA, Taylor DP, Eison MS, Stanton HC. Pharmacology and neurochemistry of buspirone. J Clin Psychiatry 1982;43:11–16.

57. Rickels K. Antianxiety therapy: potential value of long-term treatment. J Clin Psychiatry 1987;48(Suppl):7–11.

58. Rickels K, Weisman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982; 43(12,Sect.2):81–86.

59. Robinson DS, Rickels K, Feighner J, et al. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990;10(3,Suppl):67S–76S.

60. Sanghera MK, McMillen BA, German DC. Buspirone, a nonbenzodiazepine anxiolytic, increases locus coeruleus noradrenergic neuronal activity. Eur J Pharmacol 1982;86(1):107–110.

61. Schneier F, Campeas R, Fallon B, et al. Buspirone in social phobia. Presented at the 17th Congress of Collegium Internationale Neuro-Psychopharmacologicum, Sept. 1991; Kyoto, Japan (abst).

62. Schreiber R, DeVry J. 5-HT1A receptor ligands in animal models of anxiety, impulsivity, and depression: multiple mechanisms of action? Prog Neuro-Psychopharmacol Biol Psychiatry 1993; 17(1):87–104.

63. Schweizer E, Rickels K. Buspirone in the treatment of panic disorder: a controlled pilot comparison with clorazepate. J Clin Psychopharmacol 1988;8(4):303.

64. Sheehan DV, Raj AB, Sheehan KH, Soto S. Is buspirone effective for panic disorder? J Clin Psychopharmacol 1990;10(1):3–11.

65. Sills MA, Wolfe BB, Frazer A. Determination of selective and nonselective compounds for the 5-HT1a and 5-HT1B receptor subtypes in rat frontal cortex. J Pharmacol Exp Ther 1984;231:480–487.

66. Sprouse JS, Aghajanian GK. Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse 1987;1:3–9.

67. Strand M, Hetta J, Rosen A, et al. A double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry 1990;51 (Suppl):40–45.

68. Targum SD. Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder. Biol Psychiatry 1990;28(1):21–34.

69. Tollefson GD, Montague-Clouse J, Tollefson SL. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol 1992;12(1):19–26.

70. Trulson ME, Eubanks EE, Jacobs BL. Behavioral evidence for supersensitivity following destruction of central serotonergic nerve terminals by 5,7-dihydroxytryptamine. J Pharmacol Exp Ther 1976;198:23–32.

71. Tye NC, Iversen SD, Green AR. The effects of benzodiazepines and serotonergic manipulations on punished responding. Neuropharmacology 1979;18:689–695.

72. Verge D, Daval G, Marcinkiewicz M, et al. Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J Neurosci 1986;6:3474–3482.

73. Winslow JT, Insel TR. Serotonergic modulation of the rat pup ultrasonic isolation call: studies with 5-HT1 and 5-HT2 receptor subtype-selective agonists and antagonists. Psychopharmacology 1991;105(4):513–520.

74. Wright IK, Upton N, Marsden CA. Effect of potential anxiolytics on extracellular 5-HT in the ventral hippocampus of rats observed on the elevated X-maze using in vivo microdialysis. In: Rollema H, Westerink B, Drijfhout WJ, eds. Monitoring molecules in neuroscience. Proceedings of the 5th International Conference on in vivo methods, Krips Repro, Meppel; 1991:208–211.

75. Zitrin CM, Klein DF, Woerner MG, Ross DC. Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 1983;40:125–138.